Do unexpected or multiple positive paraneoplastic antibody results need orthogonal confirmation?

Unexpected paraneoplastic antibody results are clinically important because they can prompt cancer searches, immunotherapy, and major diagnostic labeling. Commercial line-blot reactivity alone is often insufficient to establish a paraneoplastic neurologic syndrome (PNS), particularly without a compatible neurologic presentation.

Clinical evidence

• Commercial line blots have substantial nonconfirmation rates. In one EUROLINE PNS 12 Ag evaluation, only 56/186 positive results (30.1%) were confirmed by independent reference methods; across EUROLINE and PNS+2 testing, confirmation was 110/369 (29.8%).
• Performance differs markedly by antigen: confirmation was 65.0% for Hu but only 5.8% for Yo in the same evaluation. Thus, a “positive panel” is not a uniform diagnostic finding.
• Clinical relevance is far higher when a line-blot result is corroborated by tissue-based testing: definite PNS occurred in 91% of concordant cases versus 8% of line-blot-only positives. One cohort reported a clinical positive predictive value of only 14.2% for positive EUROLINE results.

Phenotype, specimen, and signal strength

• A phenotype–antibody mismatch lowers pretest probability and therefore the positive predictive value of serology. Nonconfirmed immunoblot positives commonly occurred without cancer or with incongruent syndromes.
• Weak reactivity is particularly unreliable: none of 27 weakly positive EUROLINE sera was orthogonally confirmed.
• Isolated serum positivity also needs caution; probable/definite autoimmune encephalitis or PNS occurred in 31% with serum-only positivity versus 91% with CSF-only positivity in relevant cohorts.

Confirmation and clinical implications

• Confirmation should use a validated, technically independent assay: tissue immunohistochemistry/immunofluorescence plus antigen-specific immunoblot for classic intracellular/onconeural antibodies, or validated cell-based assays for neuronal-surface antibodies. Paired serum/CSF testing can further clarify interpretation.
• Bottom line: Unexpected, multiple, weak, serum-only, or phenotype-incongruent commercial line-blot positives should not alone diagnose PNS or drive immunotherapy or extensive malignancy investigation; orthogonal confirmation and phenotype-led interpretation are warranted.